University of Kentucky Markey Cancer Center researchers presented promising results from an early-stage clinical trial ...

Real Housewives of Beverly Hills alum Teddi Mellencamp celebrated the end of her radiation treatments as she continues to ...

Real Housewives of Beverly Hills alum Teddi Mellencamp shared more bad news amid her ongoing battle with cancer as doctors found new tumors that are Stage 4.

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept Therapeutics (CORT) shares rallied 109.1% in the last trading session to close at $114.22. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.